World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
84
Citations
39536
World Ranking
14853
National Ranking
7511

Richard R. Furman publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Richard R. Furman sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 448 publications — 49th percentile

49% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Richard R. Furman D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Richard R. Furman sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 84 D-Index — 27th percentile

27% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Richard R. Furman is affiliated with NewYork-Presbyterian Hospital in the United States and has contributed extensively to research in the field of medicine, particularly focusing on chronic lymphocytic leukemia (CLL) and related hematological conditions. Their scholarly output spans genetics, pathology and forensic medicine, oncology, molecular biology, and immunology.

Furman's research primarily addresses topics including chronic lymphocytic leukemia research, lymphoma diagnosis and treatment, immunodeficiency and autoimmune disorders, chronic myeloid leukemia treatments, CAR-T cell therapy research, monoclonal and polyclonal antibodies research, and advanced breast cancer therapies.

Frequent publication venues for Furman include Blood, the Journal of Clinical Oncology, Haematologica, Blood Advances, and Clinical Lymphoma Myeloma & Leukemia. They have a significant presence in Blood with 29 publications and also maintain consistent contributions in other key journals focused on oncology and hematology.

Among their recent papers are:

  • Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial, 2021, Journal of Clinical Oncology
  • Outcomes of COVID-19 in Patients with CLL: A Multicenter International Experience, 2020, Blood
  • Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study, 2020, Clinical Cancer Research
  • Detailed Safety Profile of Acalabrutinib vs Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia in the ELEVATE-RR Trial, 2023, Blood
  • Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia, 2021, Blood

Furman collaborates frequently with other researchers, with prominent coauthors including Jennifer R. Brown, John N. Allan, John C. Byrd, Paolo Ghia, and Peter Hillmen, with collaboration counts ranging from 16 to 25 joint works.

Best Publications

  • Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

    John C. Byrd;Richard R. Furman;Steven E. Coutre;Ian W. Flinn

  • Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

    Richard R. Furman;Jeff P. Sharman;Steven E. Coutre;Bruce D. Cheson

  • Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

    J. C. Byrd;J. R. Brown;Susan O'Brien;J. C. Barrientos

  • Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome

    C.M. Legendre;C. Licht;P. Muus;L.A. Greenbaum

  • Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

    Ranjana H. Advani;Joseph J. Buggy;Jeff P. Sharman;Sonali M. Smith

  • Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib

    Jennifer A. Woyach;Richard R. Furman;Ta Ming Liu;Hatice Gulcin Ozer

  • Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.

    Kenneth R. Carson;Andrew M. Evens;Elizabeth A. Richey;Thomas M. Habermann

  • Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

    John C. Byrd;Bonnie Harrington;Susan O'Brien;Jeffrey A. Jones

  • Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.

    Jason A. Dubovsky;Kyle A. Beckwith;Gayathri Natarajan;Jennifer A. Woyach

  • Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.

    John C. Byrd;Richard R. Furman;Steven E. Coutre;Jan A. Burger

  • Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia

    William G. Wierda;Thomas J. Kipps;Jiří Mayer;Stephan Stilgenbauer

  • Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.

    Jennifer R. Brown;John C. Byrd;Steven E. Coutre;Don M. Benson

  • Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study

    Owen A. O'Connor;Barbara Pro;Lauren Pinter-Brown;Nancy Bartlett

  • Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

    Susan O'Brien;Richard R Furman;Steven E Coutre;Jeff P Sharman

  • Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3′ Splice Site Selection through Use of a Different Branch Point

    Rachel B. Darman;Michael Seiler;Anant A. Agrawal;Kian H. Lim

  • Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies

    Christoph Licht;Larry A. Greenbaum;Petra Muus;Sunil Babu

  • Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma

    Peter Martin;Amy Chadburn;Paul Christos;Karen Weil

  • Single-Agent Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia: A 5-Year Experience

    Susan O'Brien;Susan O'Brien;Richard R. Furman;Steven Coutre;Ian W. Flinn

  • Bortezomib Plus CHOP-Rituximab for Previously Untreated Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma

    Jia Ruan;Peter Martin;Richard R. Furman;Shing M. Lee

  • Modulation of NF-κB Activity and Apoptosis in Chronic Lymphocytic Leukemia B Cells

    Richard R. Furman;Zahra Asgary;John O. Mascarenhas;Hsiou-Chi Liou

Frequent Co-Authors

John P. Leonard
John P. Leonard Cornell University
John C. Byrd
John C. Byrd University of Pittsburgh Cancer Institute
Steven Coutre
Steven Coutre Stanford University
Morton Coleman
Morton Coleman Cornell University
Susan O'Brien
Susan O'Brien University of California, Irvine
Peter Hillmen
Peter Hillmen St James's University Hospital
Jennifer R. Brown
Jennifer R. Brown Harvard University
Ian W. Flinn
Ian W. Flinn Sarah Cannon Research Institute
William G. Wierda
William G. Wierda The University of Texas MD Anderson Cancer Center
Thomas J. Kipps
Thomas J. Kipps University of California, San Diego

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in exploring alternative or complementary paths within healthcare, there are several related online degree and certification programs to consider. For those pursuing nursing, there are online bsn programs for non nurses that provide a flexible route to becoming a Registered Nurse, especially for individuals with a non-nursing background.

Not everyone needs to take traditional entrance exams to start their nursing journey. Some students may prefer a nursing school that doesn't require teas, removing a common barrier to entry and streamlining the admission process.

For those interested in non-clinical roles, healthcare administration offers a strong career outlook. Many schools now offer an online healthcare administration degree, ideal for aspiring leaders aiming to manage healthcare organizations.

Another rapidly growing healthcare field is medical billing and coding. Accredited medical billing and coding schools online help students gain necessary skills for essential back-office roles, often with financial aid options.

Best Scientists Citing Richard R. Furman

Trending Scientists

Recently Published Articles